Pulmonary Rehabilitation in Patients with Neuromuscular Disease by Kang, Seong-Woong
Yonsei Medical Journal
Vol. 47, No. 3, pp. 307 - 314, 2006
Yonsei Med J Vol. 47, No. 3, 2006
In neuromuscular disease (NMD) patients with progressive
muscle weakness, respiratory muscles are also affected and
hypercapnia can increase gradually as the disease progresses.
The fundamental respiratory problems NMD patients experi-
ence are decreased alveolar ventilation and coughing ability.
For these reasons, it is necessary to precisely evaluate pulmo-
nary function to provide the proper inspiratory and expiratory
muscle aids in order to maintain adequate respiratory function.
As inspiratory muscle weakening progresses, NMD patients
experience hypoventilation. At this point, respiratory support
by mechanical ventilator should be initiated to relieve res-
piratory distress symptoms. Patients with adequate bulbar
muscle strength and cognitive function who use a non-invasive
ventilation aid, via a mouthpiece or a nasal mask, may have
their hypercapnia and associated symptoms resolved. For a
proper cough assist, it is necessary to provide additional
insufflation to patients with inspiratory muscle weakness before
using abdominal thrust. Another effective method for managing
airway secretions is a device that performs mechanical insuffla-
tion-exsufflation. In conclusion, application of non-invasive
respiratory aids, taking into consideration characterization of
respiratory pathophysiology, have made it possible to maintain
a better quality of life in addition to prolonging the life span
of patients with NMD.
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INTRODUCTION
Respiratory complications are a leading cause of
morbidity and mortality in neuromuscular dis-
eases (NMD). Patients with NMD are known to
develop restrictive pulmonary disease pattern due
to the progressive weakening of respiratory
muscles.
1-3 Periodic monitoring of lung volumes
and maximal respiratory pressures to assess the
strength of the respiratory muscles is necessary
for these patients. Muscle weakness results in
respiratory complications and bring about alveo-
lar hypoventilation, eventually inducing hyper-
capnia.
3-5 When hypercapnia occurs, patients
experience symptoms such as morning headache,
nightmares, daytime somnolence, and a decreased
attention span. The fundamental respiratory pro-
blems NMD patients have are decreased alveolar
ventilation and coughing ability. For these rea-
sons, it is necessary to perform a precise evalua-
tion of pulmonary function in order to provide
the proper inspiratory and expiratory muscle aids
to maintain adequate respiratory function.
CHRACTERISTICS OF RESPIRATORY DYS-
FUNCTION IN NMD
In NMD patients with progressive muscle
weakness, respiratory muscles are also affected
and hypercapnia can increase gradually along
with the disease. Even in the non-progressive
form of the disease, muscle weakness can be
aggravated by the overall aging process and
hypercapnia is associated with aging as well.
6 If
any kind of respiratory complications occur in
these patients, the respiratory work load increases,
which can induce decompensation of respiratory
muscles. In such cases, supportive ventilation
should be provided to avoid respiratory muscle
fatigue.
7 If support is not provided, acute respi-
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ratory failure can be induced due to the abrupt
fall in pH. Management of respiratory muscle
fatigue is the key factor in the respiratory care of
NMD. Weaning from ventilatory support after
resolution of respiratory complications can be
frustrating for a patient with advanced respiratory
muscle weakness because of recurring respiratory
muscle fatigue. In this situation, a patient may
need reintubation and supportive ventilation
repeatedly and may eventually receive a trache-
ostomy tube for long term support. In such
patients, instead of totally weaning them, it would
be better to provide noninvasive ventilatory
support via nasal mask or mouthpiece after
removal of the intubation tube. By providing
ventilatory aid through noninvasive means, we
can prevent respiratory muscle decompensation.
7
When airway secretions increase due to res-
piratory tract infection, normal people can clear
out the secretions through coughing and they
seldom develop further complications such as
pneumonia.
8 Patients with NMD, however, tend
to develop atelectasis and pneumonia easily due
to an ineffective cough.
9 The further expiratory
muscle weakness has progressed, the greater the
likelihood of reduced coughing ability to clear out
secretions is. In addition to this, reduced respira-
tory compliance leading to contracture of the lung
parenchyme and chest wall affects the inspiratory
phase of coughing.
10,11 Patients with limited lung
expansion due to the contracture of the lung
parenchyme find it more difficult to clear respira-
tory secretions.
12 This can cause further problems
when coughing assistance is needed. In order to
induce effective coughing, sufficient inhalation of
air should be first established. A precise assess-
ment of the patient and a thorough understanding
of the respiratory pathophysiology associated
with NMD can be the basis of ventilation assis-
tance needed to enable effective clearance of
airway secretions.
ASSESSMENT
Respiratory failure in NMD patients is not
attributed to problems in the lung parenchyme,
but to the weakened respiratory muscles. Ade-
quate pulmonary evaluation considering this
should be taken. Along with the basic pulmonary
function evaluation, additional assessment and
precautions for patients are as follows.
Maximal Inspiratory and Expiratory Pressure
In many NMDs, weakness involves not only the
skeletal muscles in extremities but also the
respiratory muscles. Respiratory muscle weakness
eventually results in overall respiratory dysfunc-
tion, interrupting the activities of daily life. In
many cases, respiratory distress symptoms do not
manifest themselves along with the progression of
respiratory muscle weakness.
13 For this reason,
periodic evaluation of respiratory muscle function
is needed in the management of NMDs. Maximal
static pressure, the measuring of maximal inspira-
tory and expiratory pressure, is an indirect way to
assess respiratory muscle power. It shows subtle
changes associated with early stages of disease
when the standard spirometer measurement does
not detect any abnormalities.
2,4 Inspiratory muscle
weakness diminishes the capacity of lungs and the
chest wall to expand.
14 However, total lung capa-
city does not begin decreasing until the inspiratory
muscle power declines to less than 50% of normal.
13 Consequently, except in cases with advanced
muscle weakness, measuring maximum inspiratory
pressure is recommended for early detection of
inspiratory muscle weakness.
14 Maximum expira-
tory pressure is measured by total lung capacity,
where the patient takes the deepest breath possible
then blows out all of the air through a cylindrical
mouthpiece into a static pressure meter. Similarly,
maximum inspiratory pressure is measured by
residual volume, where the patient blows out all of
their air then inhales as much air as possible. For
NMD patients experiencing respiratory muscle
weakness, measuring maximum static pressure is a
more suitable landmark for assessing patients and
establishing further therapeutic plans.
3,15
Vital capacity (VC)
Measuring VC is the most fundamental land-
mark in pulmonary function evaluation that helps
to make further therapeutic plans. The VC values
can show variations according to a patient's posi-
tion or indicate deterioration in their respiratoryPulmonary Rehabilitation in Neuromuscular Disease
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muscle function. Patients with amyotrophy lateral
sclerosis (ALS) who have diaphragm weakness
show greater value in sitting position.
16,17 In con-
trast, cervical cord injury patients lacking diaph-
ragm weakness have a higher VC measurement
when in a supine position.
18-20 Thus, NMD patients
should have their VC measured both in sitting and
supine positions because of the possible measure-
ment variations. Lower cervical cord injury
patients mainly breathe through the diaphragm
due to intercostal or abdominal muscle par-
alysis.
18,19 Paralysis of the expiratory muscle group
will not trigger contraction of expiratory muscles
when trying to breathe out air after full inspiration.
Therefore, expiration while in a sitting position
occurs passively by deflation of the fully inhaled
lungs and thoracic wall through recoiling. In
addition, descended abdominal contents, along
with gravity, reduce the excursion of the diaph-
ragm.
18-20 This could explain the reduced VC mea-
surement seen in a sitting position versus supine.
In many ALS patients, diaphragm weakness is
frequently accompanied in accordance with the
progressive respiratory muscle weakness. In a
supine position, increased pulmonary circulation
triggers a reduction in the air volume inhaled into
the thorax. This, in conjunction with compression
of the diaphragm by abdominal contents, induces
a decrease in VC. This phenomenon is also ob-
served in normal healthy people. Previous studies
report that normal healthy people experience a
decrease in VC by 7.5% when in a supine position.
17,21 In NMDs with progressive muscle weakness
like ALS, VC in a supine position is closely related
to the progressive weakness of the diaphragm.
Discrepancies in VC measurements due to the
different positions can be a possible landmark that
reflects the degree of diaphragmatic weakness.
In addition to positional variations, the use of
spinal orthosis, which is used to correct scoliosis
in NMD patients, can limit thoracic movements.
VC should be measured with the braces on and
off to determine the application of the orthosis.
22
Maximum insufflation capacity (MIC)
Weakened respiratory muscles can neither ex-
pand the lung up to its maximal capacity nor col-
lapse the lung to its minimal residual volume.
23 If
the thoracic wall does not experience a full
expansion for a long period of time, the thoracic
muscle component shortens and muscle fibrosis
progresses, all of which reduce the compliance of
thoracic wall. Compliance of the lung parenchyme
may be reduced by microatelectasis of alveoli.
23,24
Changes in compliance may cause serious pro-
blems in maintaining pulmonary health by re-
ducing the capacity to cough and clear secre-
tions.
10 Therefore, measuring the maximum insuf-
flation capacity and comparing it to actual VC can
be an indirect method to determine the compli-
ance of the respiratory system.
25
In order to measure MIC, a patient is asked to
inhale as much air as possible, then an extra
volume of air is delivered by a manual resusci-
tator bag using either an oronasal mask or a
mouthpiece. After holding in the additional air,
the patient is then asked to blow out as much air
as possible through the spirometer.
22,25
Peak cough flow (PCF)
Coughing is one of the most important protec-
tive mechanisms in our body. It clears out airway
secretions to prevent further complications such as
pneumonia.
8 Reduced coughing capacity, along
with respiratory muscle weakness, may cause res-
piratory complications by not allowing satisfactory
removal of bronchial secretions.
9 Coughing capa-
city can be assessed by having the person cough
as forcefully as possible through the peak flow
meter. Only people who show PCF values greater
than 160 L/min, whether unassisted or manually
assisted, can efficiently eliminate bronchial secre-
tions. People with maximum assisted PCF values
of 200-250 L/min, whether unassisted or manually
assisted, under normal conditions usually have
difficulty maintaining the minimum assisted PCF
value required for removal of secretion under con-
ditions of respiratory infection or general anes-
thesia.
9,26 Therefore, measuring PCF values and
establishing further treatment plans following PCF
measurement is fundamental for NMD patients.
Measurements of oxyhemoglobin saturation
(SaO2) and end-tidal CO2 (EtCO2)
NMD patients with weakened respiratory mus-Seong-Woong Kang
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cle power are often exposed to a state of chronic
hypoventilation. The acute onset of hypercapnia
decreases systemic pH, triggering the respiratory
drive by inducing deep breathing. However, in
chronic hypercapnia, the triggering effect is some-
what muted due to the compensatory work of the
kidney.
27 Providing only oxygen to raise the SaO2
to a patient in this condition may induce more
shallow breath, thereby aggravating hypercapnia
and eventually causing CO2 narcosis.
27 Accord-
ingly, treatment of NMD patients with oxyhemo-
globin desaturation should be initiated with
consideration of their CO2 status.
Arterial blood gas analysis (ABGA) is generally
performed to assess the overall ventilatory state of
the patient. However in neuromuscular disease,
serial measurements of SaO2 and EtCO2, under
different circumstances with a pulse oxymeter and
capnometer, is recommended for a more complete
understanding of the ventilatory state.
22 For i-
nstance, an ALS patient with weak diaphragm
movement shows greater VC in a sitting position
than a supine position.
16,17 Conversely, a cervical
cord injury patient has a greater VC value in a
supine position.
18,20 Even in the same patient,
ventilatory drive is depressed when sleeping.
28
Measurements should also occur when the patient
is in different states of wakefulness, due to the
depression of the ventilatory drive during sleep.
The differences in values in this set of measure-
ments are as important as understanding mea-
surement variation due to differences in position.
Arterial blood gas analysis is an invasive method
and the associated pain may induce hyperventila-
tion, thereby altering the data. Therefore, a non-
invasive method of measurement can provide
superior information for management plans.
RESPIRATORY MUSCLE AIDS
Inspiratory muscle aids (ventilation assist)
As inspiratory muscle weakness progresses,
NMD patients experience hypoventilation symp-
toms such as sleeping disturbance, morning
headache, daytime somnolence, nightmare, and
anxiety due to hypercapnia. At this point, ven-
tilation assist by mechanical ventilator should be
initiated to relieve respiratory distress. Con-
ventional invasive methods such as intubation or
an indwelling tracheostomy tube can be a
psychological burden for both the patients and
their caregivers.
29 Even when mechanical ven-
tilator is needed, physicians and guardians, as
well as patients, tend to hesitate and postpone
initiating treatment due to the invasiveness and
subsequent psychological despair. This causes the
ventilatory status of the patient to deteriorate,
thereby necessitating the need to undergo an
invasive method for management of their serious
condition. If a non-invasive ventilatory assist
method, through a mouthpiece or a nasal mask,
is provided to the patient at the beginning as an
alternative choice to relieve the respiratory dis-
tress symptoms, patient would accept the use of
mechanical ventilator more easily. In most cases,
non-invasive ventilatory assist is sufficient to
resolve hypercapnia and its associated symp-
toms.
30,31 Intermittent positive pressure ventila-
tion (IPPV) is a commonly used non-invasive
assist. These types of assist can be successfully
applied to a patient with very weak respiratory
muscles if they have adequate bulbar muscle
power. The quality of life for a tracheostomized
ventilator user can be much improved by swit-
ching to non-invasive IPPV.
32,33 Even when non-
invasive IPPV can no longer substitute for in-
vasive IPPV in some patients, it at least is a way
to postpone tracheostomy without hypercapnia
symptoms up to that point in time.
Advantages and limitations of non-invasive IPPV
Studies comparing the results of noninvasive
versus invasive ventilatory assist have reported
Fig. 1. Patient with congenital muscular dystrophy using
nasal intermittent positive pressure ventilation.Pulmonary Rehabilitation in Neuromuscular Disease
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patients that received non-invasive IPPV showed
fewer respiratory complications, lower admission
rates, and shorter duration in their hospital stay
when admitted.
29,30 Another study comparing
these two methods has reported that people
generally favor the non-invasive method and this
method is superior in aspects of convenience,
safety, general comfort, speech, preservation of
swallowing function, sleeping, and appearance.
29,31 Research on the pathophysiology of applying
noninvasive ventilator has determined the use of
non-invasive ventilator can increase the maximum
inspiratory pressure in patients with chronic
alveolar hypoventilation as well as temporally
increase VC.
34,35 In addition, the study also re-
ported several other possible advantages such as
relieving alveolar hypoventilation symptoms,
normalizing the value of ABGA, increasing en-
durance of respiratory muscles, reducing the
admission rate and the occurrence of concomitant
respiratory complications, and delaying the time
of tracheostomy, all by applying non-invasive
ventilation.
30,31,36,37 Despite these advantages, non-
invasive ventilator cannot be applied to all
patients with ventilatory failure. Typical examples
are patients with cognitive impairment and those
with severe bulbar muscle palsy.
32 Patients with
impaired cognitive function can not cooperate
well enough to perform assistive coughing or use
assistive devices to remove airway secretions. This
inability to comply can put the patients in dan-
gerous condition.
32 In order to apply non-invasive
ventilation without undergoing tracheostomy, the
bulbar muscle should be spared in some mea-
sure.
32 Patients with bulbar muscle palsy, such as
bulbar dominant ALS patients, find it difficult to
increase intrapleural pressure with the glottis
closed during an assistive coughing maneuver.
38
In this case, it is not possible to remove airway
secretions without using a device or patients
would experience recurrent saliva aspiration,
often a major cause of aspiration pneumonia.
33 It
is inevitable for such a patient to undergo trache-
ostomy and have invasive ventilatory assistance
applied.
33
Mechanical ventilators used in non-invasive ventila-
tion
Mechanical ventilators can be classified as a
body ventilator which directly put pressure on
body for mechanical ventilation and a positive
pressure ventilator which directly delivers air into
trachea. Body ventilators had once been the first
line therapy as a long term assistive ventilation
device. But with the introduction of positive pres-
sure ventilators in the mid 1950s, body ventilators
became less attractive because of their limited
portability and patient care.
39 Portable ventilators
used in non-invasive IPPV can be divided into
two categories: pressure limited and volume lim-
ited ventilators. Volume limited ventilators deliver
a preset volume of air regardless of air leakage
through the mouth or nose and the maximal
airway pressure reading on the gauge of the
ventilator depends on the volume of delivered air,
leakage at the interface, and elasticity of the lung.
PLV series (Respronics, USA), LP-10 (Aequitron
medical Inc., USA), and LTV series (Pulmonetic
Systems, Inc., USA) are examples of commonly
used volume limited portable ventilator. The most
common pressure limited ventilator is bi-level
positive airway pressure (BiPAP) device. It is
possible to preset the inspiratory and expiratory
positive pressure separately on a BiPAP and the
difference between these two pressures is
considered the degree of assistive ventilation. In
general, the difference between pressures is set
between 5-7 cmH2O. Although this setting is
suitable for people with a obstructive pattern
respiratory disease such as sleep apnea, it cannot
help those who are in a chronic alveolar hypo-
ventilative state due to weakened respiratory
muscles.
33 Pressure limited ventilators can neither
deliver sufficient air to those with atelectasis or
increased airway resistance due to endotracheal
secretions, nor provide the capability to perform
air stacking to maintain pulmonary compliance.
Therefore, it is recommended for NMD patients to
use volume limited ventilators for non-invasive
mechanical ventilation.
33
Glossopharyngeal breathing (GPB)/Frog breathing
GPB is a breathing maneuver that requires
gulping boluses of air into the lung by using the
tongue and pharyngeal muscles. It can be useful
for the patient with ventilatory insufficiency and
is especially helpful when mechanical ventilator
stops working unexpectedly.
33 GPB consists of 6-9Seong-Woong Kang
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gulps of air, with 60-200 mL of air in each gulp.
Expiratory muscle aids
Expiratory muscle aids are either a maneuver or
a mechanical device used to remove endotracheal
secretions. Proper coughing is prerequisite to
clearing endotracheal secretions or to removing a
mucus plug. The PCF of normal, healthy people
reads above 6-12 L/sec. Deep inspiration and
sufficient intrapleural pressure are required to
induce the normal coughing process.
40 Therefore,
insufflating additional pre-cough volume is essen-
tial for the patient with decreased VC to induce
effective coughing.
11,41 A PCF over 160 L/min
should be maintained to eliminate endotracheal
secretions effectively.
42,43 There are diverse
methods and devices for managing airway
secretions, however, this session will primarily
focus on the methods especially useful in NMDs.
Assistive coughing
Coughing is an essential function for elimi-
nating tracheal secretions, and reduced function
may cause respiratory complications such as
pneumonia. Eventually, defective coughing may
be a primary cause of mortality in NMD patients
with inspiratory and expiratory muscle weakness
or bulbar muscle palsy. Therefore, a proper
coughing assist should be provided to those NMD
patients with respiratory muscle weakness. A
manually assisted cough is the most commonly
used assisted coughing method. After taking a
deep breath, the patient is asked to cough as
forcefully as possible while a simultaneously
timed abdominal thrust is performed. Although
taking in a sufficient volume of air should come
before coughing,
11,41 many NMD patients find it
difficult to inhale enough air due to the weakened
inspiratory muscles. Therefore, it is necessary to
provide additional insufflation through a manual
resuscitator bag to those with inspiratory muscle
weakness before trying the abdominal thrust.
11,41
Cough assist device (Cough assist
TM/Mechanical in-
sufflator-exsufflator)
Cough assist
TM (JH Emerson Co., Cambridge,
MA) operates under the same principle as that of
a vacuum cleaner, which generates strong expira-
tory flow through an instant application of
negative pressure after maximum insufflation of
the lung with positive pressure. Patients can clear
airway secretions easily through applying Cough
assist
TM via an oronasal mask without undergoing
tracheostomy.
41 It can be a more efficient way of
clearing secretions for those with a tracheostomy
tube than using manual suction by a catheter.
Cough assist
TM eliminates respiratory secretions
by alternating 40 cmH2O of positive pressure with
-40 cmH2O of negative pressure, which generates
approximately 10 L/sec of air flow velocity be-
cause of the pressure difference.
11,44 It is an essen-
tial device for non-invasive mechanical ventilator
users who have very weak coughing capacity
because clearing airway secretions is possible only
by applying Cough assist
TM via oronasal mask.
41,45
The effect of this kind of device has already been
proven through many experimental studies. In an
experiment, radioactive material was inhaled into
the lung of a dog and, after a six-minute appli-
cation of the cough assisting device, the inhaled
material had been completely removed.
46 In an-
other study, values of PCF in several different
situations were compared and the authors re-
ported the measured PCF values were much
higher in the group using the cough assisting
device than the measurements taken in the groups
using different manual assisted coughing tech-
niques.
30,41,47 Cough assist
TM not only generates a
higher PCF, thereby increasing the overall
removal of bronchial secretions, but also elimi-
nates the irritation and/or damage to the airway
caused by catheter suction. Furthermore, when
applied postoperatively, it can clear bronchial
secretions without inducing wound site pain
Fig. 2. Cough Assist
TM is a commercially available device
which performs mechanical issufflation-exsufflation.Pulmonary Rehabilitation in Neuromuscular Disease
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caused by generating an expiratory muscle con-
traction.
CONCLUSION
As with other rehabilitative management pro-
gram applied in different fields of medicine,
active application of a pulmonary rehabilitation
program can actually relieve patients' respiratory
symptoms, prevent possible complications, and
eventually improve the quality of life for the
patient. Until now, NMD patients with ALS,
myopathy, or spinal muscular atrophy, those in
greater need of pulmonary rehabilitation, are
often overlooked due to preoccupation with the
nature of their disease. People tend to think these
sets of patients are untreatable. Their disease is
incurable, but their symptoms are treatable. We
can assist them in many ways, especially in the
management of their pulmonary complications. If
there is an accurate understanding of the disease's
pathophysiology and a thorough assessment of
the patient occurs early on, minimization of likely
respiratory complications can be possible through
proper ventilatory and coughing support. Re-
duced respiratory complications can actually
decrease the mortality rate of NMD patients.
Together with the medical advantages, a patient's
quality of life can be greatly enhanced by
adopting non-invasive aids even if the aid will be
used long term. In conclusion, use of non-invasive
respiratory aids, taking into account the charac-
terization of respiratory pathophysiology, have
made it possible to enhance quality of life as well
as prolong the life span of NMD patients.
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